<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85080</article-id><article-id pub-id-type="doi">10.7554/eLife.85080</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>T Cells</subject></subj-group></article-categories><title-group><article-title>Ready and waiting to go</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-208757"><name><surname>Rivino</surname><given-names>Laura</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6213-9794</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Laura Rivino</bold> is in the School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol, United Kingdom</p></bio></contrib><contrib contrib-type="author" corresp="yes" id="author-170554"><name><surname>Wooldridge</surname><given-names>Linda</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6213-347X</contrib-id><email>Linda.Wooldridge@bristol.ac.uk</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Linda Wooldridge</bold> is in the Bristol Veterinary School, Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0524sp257</institution-id><institution>School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol</institution></institution-wrap><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0524sp257</institution-id><institution>Bristol Veterinary School, Faculty of Health Sciences, University of Bristol</institution></institution-wrap><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>06</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85080</elocation-id><permissions><copyright-statement>© 2023, Rivino and Wooldridge</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Rivino and Wooldridge</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85080-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.82050" id="ra1"/><abstract><p>Some T cells that have been activated by a herpesvirus can also respond to SARS-CoV-2, even if the original herpesvirus infection happened before the COVID-19 pandemic.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>heterologous immunity</kwd><kwd>cross-reactivity</kwd><kwd>T cells</kwd><kwd>HCMV</kwd><kwd>SARS-CoV-2</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Some T cells that have been activated by a herpesvirus can also respond to SARS-CoV-2, even if the original herpesvirus infection happened before the COVID-19 pandemic.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Pothast CR, Dijkland RC, Thaler M, Hagedoorn RS, Kester MGD, Wouters AK, Hiemstra PS, van Hemert MJ, Gras S, Frederik Falkenburg JH, Heemskerk MHM. 2022. SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells. <italic>eLife</italic> <bold>11</bold>:e82050. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.82050">10.7554/eLife.82050</ext-link>.</p></boxed-text><p>Cells called T cells play an important role in protecting the body against infection by removing pathogens that may cause harm. Two major types of T cell are involved in the response to a viral infection. Both become activated when their receptors recognize short peptides from viral proteins called ‘epitopes’: CD8 T cells directly attack infected cells, whereas CD4 T cells help other immune cells (called B cells) to produce antibodies. Once the infection has been eliminated, some of these CD8 and CD4 T cells survive in the body as long-lived memory T cells which can immediately respond if the virus invades again.</p><p>Previous studies found that some blood samples taken before the COVID-19 pandemic already contained T cells that could recognize the SARS-CoV-2 virus (<xref ref-type="bibr" rid="bib2">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Le Bert et al., 2020</xref>). However, researchers still do not fully understand how these T cells arose, or how they impact immunity and disease outcomes for COVID-19 patients.</p><p>One possibility is that these pre-existing T cells arose due to a phenomenon called heterologous immunity (<xref ref-type="bibr" rid="bib10">Welsh et al., 2010</xref>). This is when CD4 and CD8 T cells activated by a specific pathogen ‘cross-react’ and respond to epitopes from a different virus (<xref ref-type="bibr" rid="bib5">Mason, 1998</xref>). It was previously thought that coronaviruses already circulating in the population before the pandemic were responsible for the existence of some T cells that could recognise SARS-CoV-2 (<xref ref-type="bibr" rid="bib2">Grifoni et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Swadling et al., 2022</xref>). Now, in eLife, Cilia Pothast (Leiden University Medical Center), Mirjam Heemskerk (also at Leiden) and colleagues report that another group of viruses may have also been involved (<xref ref-type="bibr" rid="bib7">Pothast et al., 2022</xref>).</p><p>The team hypothesised that some of the T cells specific to SARS-CoV-2 had been activated by a herpesvirus called human cytomegalovirus (HCMV). This pathogen is highly prevalent in the population and has also been linked to changes in the severity of COVID-19 symptoms (<xref ref-type="bibr" rid="bib1">Alanio et al., 2022</xref>). To investigate, they stimulated pre-pandemic blood samples with different segments of SARS-CoV-2 proteins. This led them to discover a population of ‘cross-reactive’ CD4 and CD8 T cells that can recognize epitopes from both SARS-CoV-2 and HCMV (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Infection with human cytomegalovirus (HCMV) can stimulate T cells that can recognise SARS-CoV-2.</title><p>When individuals are infected with HCMV (virus shown in pink), the population of T cells that can detect this virus expands (T cells shown here in purple). Cross-reactivity is a well-known feature of the immune response. Through this process, HCMV infection can activate T cells (shown here in green) that can recognise both HCMV and another pathogen – including the SARS-CoV-2 virus, even if the HCMV infection happened before the COVID-19 pandemic. These cross-reactive T cells may be able to contribute to the immunity of an individual to SARS-CoV-2, as well as to how COVID-19 affects their body.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85080-fig1-v1.tif"/><attrib>Image credit: Created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">BioRender.com</ext-link>.</attrib></fig><p>Pothast et al. found that this cross-reactivity was due to a T cell receptor that is expressed in multiple individuals. However, there are very few similarities between the amino acid sequences of the SARS-CoV-2 and the HCMV epitopes, bringing into question how this T cell receptor can detect both viruses. It may be possible to explain the molecular basis for this observation by solving crystal structures of this T cell receptor in complex with either the presented HCMV or SARS-CoV-2 epitopes.</p><p>Further experiments then revealed that the cross-reactive T cells limit the replication of SARS-CoV-2 in vitro when the virus is present at low levels. However, the cross-reactive T cells did not appear to have an activated phenotype in patients with severe COVID-19. This might be because individuals included in this study were over 60 years of age, and HCMV-specific T cells do not work as well as people get older (<xref ref-type="bibr" rid="bib6">Ouyang et al., 2004</xref>).</p><p>It has been suggested that heterologous immunity may play a beneficial role in protective immunity (<xref ref-type="bibr" rid="bib10">Welsh et al., 2010</xref>). This is consistent with a recent study showing that T cells which cross-react with SARS-CoV-2 are associated with abortive infections (when the virus fails to spread to other cells) and asymptomatic cases of COVID-19 (<xref ref-type="bibr" rid="bib9">Swadling et al., 2022</xref>). These pre-existing T cells may also enhance a person’s response to vaccines (<xref ref-type="bibr" rid="bib4">Loyal et al., 2021</xref>). However, heterologous immunity is a double-edged sword, as it can also increase the severity of some viral infections. For example, in dengue infections, cross-reactive antibodies and T cells can result in an immune response that is harmful to the body (<xref ref-type="bibr" rid="bib10">Welsh et al., 2010</xref>; <xref ref-type="bibr" rid="bib8">Screaton et al., 2015</xref>).</p><p>Further studies are needed to establish whether other pathogens (including bacteria) can stimulate T cells capable of recognising epitopes from SARS-CoV-2. In addition, studies with larger cohorts of vaccinated individuals and patients with mild or severe COVID-19 are required to define the role that these cross-reactive T cells play in protective immunity, in response to vaccination, and in disease pathology.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alanio</surname><given-names>C</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Mathew</surname><given-names>D</given-names></name><name><surname>Gouma</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Dunn</surname><given-names>T</given-names></name><name><surname>Oldridge</surname><given-names>DA</given-names></name><name><surname>Weaver</surname><given-names>J</given-names></name><name><surname>Kuri-Cervantes</surname><given-names>L</given-names></name><name><surname>Pampena</surname><given-names>MB</given-names></name><name><surname>Betts</surname><given-names>MR</given-names></name><name><surname>Collman</surname><given-names>RG</given-names></name><name><surname>Bushman</surname><given-names>FD</given-names></name><name><surname>Meyer</surname><given-names>NJ</given-names></name><name><surname>Hensley</surname><given-names>SE</given-names></name><name><surname>Rader</surname><given-names>D</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name><collab>UPenn COVID Processing Unit</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalization</article-title><source>The Journal of Infectious Diseases</source><volume>226</volume><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac020</pub-id><pub-id pub-id-type="pmid">35134186</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Ramirez</surname><given-names>SI</given-names></name><name><surname>Mateus</surname><given-names>J</given-names></name><name><surname>Dan</surname><given-names>JM</given-names></name><name><surname>Moderbacher</surname><given-names>CR</given-names></name><name><surname>Rawlings</surname><given-names>SA</given-names></name><name><surname>Sutherland</surname><given-names>A</given-names></name><name><surname>Premkumar</surname><given-names>L</given-names></name><name><surname>Jadi</surname><given-names>RS</given-names></name><name><surname>Marrama</surname><given-names>D</given-names></name><name><surname>de Silva</surname><given-names>AM</given-names></name><name><surname>Frazier</surname><given-names>A</given-names></name><name><surname>Carlin</surname><given-names>AF</given-names></name><name><surname>Greenbaum</surname><given-names>JA</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Crotty</surname><given-names>S</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><volume>181</volume><fpage>1489</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmid">32473127</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Kunasegaran</surname><given-names>K</given-names></name><name><surname>Tham</surname><given-names>CYL</given-names></name><name><surname>Hafezi</surname><given-names>M</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><name><surname>Chng</surname><given-names>MHY</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>N</given-names></name><name><surname>Linster</surname><given-names>M</given-names></name><name><surname>Chia</surname><given-names>WN</given-names></name><name><surname>Chen</surname><given-names>MIC</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Kalimuddin</surname><given-names>S</given-names></name><name><surname>Tambyah</surname><given-names>PA</given-names></name><name><surname>Low</surname><given-names>JGH</given-names></name><name><surname>Tan</surname><given-names>YJ</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title><source>Nature</source><volume>584</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2550-z</pub-id><pub-id pub-id-type="pmid">32668444</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loyal</surname><given-names>L</given-names></name><name><surname>Braun</surname><given-names>J</given-names></name><name><surname>Henze</surname><given-names>L</given-names></name><name><surname>Kruse</surname><given-names>B</given-names></name><name><surname>Dingeldey</surname><given-names>M</given-names></name><name><surname>Reimer</surname><given-names>U</given-names></name><name><surname>Kern</surname><given-names>F</given-names></name><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Mangold</surname><given-names>M</given-names></name><name><surname>Unger</surname><given-names>C</given-names></name><name><surname>Dörfler</surname><given-names>F</given-names></name><name><surname>Kadler</surname><given-names>S</given-names></name><name><surname>Rosowski</surname><given-names>J</given-names></name><name><surname>Gürcan</surname><given-names>K</given-names></name><name><surname>Uyar-Aydin</surname><given-names>Z</given-names></name><name><surname>Frentsch</surname><given-names>M</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Schnatbaum</surname><given-names>K</given-names></name><name><surname>Eckey</surname><given-names>M</given-names></name><name><surname>Hippenstiel</surname><given-names>S</given-names></name><name><surname>Hocke</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><name><surname>Miltenyi</surname><given-names>S</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>Mall</surname><given-names>MA</given-names></name><name><surname>Wenschuh</surname><given-names>H</given-names></name><name><surname>Voigt</surname><given-names>S</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Lauster</surname><given-names>R</given-names></name><name><surname>Lachman</surname><given-names>N</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Corman</surname><given-names>VM</given-names></name><name><surname>Röhmel</surname><given-names>J</given-names></name><name><surname>Meyer-Arndt</surname><given-names>L</given-names></name><name><surname>Thiel</surname><given-names>A</given-names></name><name><surname>Giesecke-Thiel</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination</article-title><source>Science</source><volume>374</volume><elocation-id>eabh1823</elocation-id><pub-id pub-id-type="doi">10.1126/science.abh1823</pub-id><pub-id pub-id-type="pmid">34465633</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A very high level of crossreactivity is an essential feature of the T-cell receptor</article-title><source>Immunology Today</source><volume>19</volume><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/s0167-5699(98)01299-7</pub-id><pub-id pub-id-type="pmid">9745202</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>Q</given-names></name><name><surname>Wagner</surname><given-names>WM</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Wikby</surname><given-names>A</given-names></name><name><surname>Remarque</surname><given-names>EJ</given-names></name><name><surname>Pawelec</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly</article-title><source>Experimental Gerontology</source><volume>39</volume><fpage>607</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2003.11.016</pub-id><pub-id pub-id-type="pmid">15050296</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pothast</surname><given-names>CR</given-names></name><name><surname>Dijkland</surname><given-names>RC</given-names></name><name><surname>Thaler</surname><given-names>M</given-names></name><name><surname>Hagedoorn</surname><given-names>RS</given-names></name><name><surname>Kester</surname><given-names>MGD</given-names></name><name><surname>Wouters</surname><given-names>AK</given-names></name><name><surname>Hiemstra</surname><given-names>PS</given-names></name><name><surname>van Hemert</surname><given-names>MJ</given-names></name><name><surname>Gras</surname><given-names>S</given-names></name><name><surname>Frederik Falkenburg</surname><given-names>JH</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells</article-title><source>eLife</source><volume>11</volume><elocation-id>e82050</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.82050</pub-id><pub-id pub-id-type="pmid">36408799</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Screaton</surname><given-names>G</given-names></name><name><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name><surname>Yacoub</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>New insights into the immunopathology and control of dengue virus infection</article-title><source>Nature Reviews Immunology</source><volume>15</volume><fpage>745</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1038/nri3916</pub-id><pub-id pub-id-type="pmid">26603900</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swadling</surname><given-names>L</given-names></name><name><surname>Diniz</surname><given-names>MO</given-names></name><name><surname>Schmidt</surname><given-names>NM</given-names></name><name><surname>Amin</surname><given-names>OE</given-names></name><name><surname>Chandran</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>E</given-names></name><name><surname>Pade</surname><given-names>C</given-names></name><name><surname>Gibbons</surname><given-names>JM</given-names></name><name><surname>Le Bert</surname><given-names>N</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Jeffery-Smith</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>CCS</given-names></name><name><surname>Tham</surname><given-names>CYL</given-names></name><name><surname>Kucykowicz</surname><given-names>S</given-names></name><name><surname>Aidoo-Micah</surname><given-names>G</given-names></name><name><surname>Rosenheim</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>MP</given-names></name><name><surname>Joy</surname><given-names>G</given-names></name><name><surname>McCoy</surname><given-names>LE</given-names></name><name><surname>Valdes</surname><given-names>AM</given-names></name><name><surname>Chain</surname><given-names>BM</given-names></name><name><surname>Goldblatt</surname><given-names>D</given-names></name><name><surname>Altmann</surname><given-names>DM</given-names></name><name><surname>Boyton</surname><given-names>RJ</given-names></name><name><surname>Manisty</surname><given-names>C</given-names></name><name><surname>Treibel</surname><given-names>TA</given-names></name><name><surname>Moon</surname><given-names>JC</given-names></name><name><surname>van Dorp</surname><given-names>L</given-names></name><name><surname>Balloux</surname><given-names>F</given-names></name><name><surname>McKnight</surname><given-names>Á</given-names></name><name><surname>Noursadeghi</surname><given-names>M</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Maini</surname><given-names>MK</given-names></name><collab>COVIDsortium Investigators</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2</article-title><source>Nature</source><volume>601</volume><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04186-8</pub-id><pub-id pub-id-type="pmid">34758478</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>RM</given-names></name><name><surname>Che</surname><given-names>JW</given-names></name><name><surname>Brehm</surname><given-names>MA</given-names></name><name><surname>Selin</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Heterologous immunity between viruses</article-title><source>Immunological Reviews</source><volume>235</volume><fpage>244</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2010.00897.x</pub-id><pub-id pub-id-type="pmid">20536568</pub-id></element-citation></ref></ref-list></back></article>